We have previously shown that constitutive activation of PDPK1 through overexpression activates RSK2‐NTKD in MCL regardless of the activation status of the RAS/MAPK/ERK pathway,24 but a mutation that activates the RAS/RAF/MEK/ERK pathway directly is rare in MCL.26, 27, 28, 29. This evidence concerns the gene RPS6KA3 and mantle cell lymphoma.